Aeglea BioTherapeutics has hired Jim Kastenmayer as general counsel.
Kastenmayer previously worked at Viela Bio as general counsel, a role in which he provided strategic guidance and legal advice on issues such as the US Food and Drug Administration approval and launch of Uplizna and the company’s acquisition by Horizon Therapeutics.
Before his time with Viela Bio, Kastenmayer held roles of increasing responsibility at AstraZeneca, including global legal director – a role in which he advised on commercialization, market access strategies and collaboration agreements, and handled legal proceedings – in addition to senior patent director. Earlier in his career, he was intellectual property counsel at MedImmune.
Aeglea is a clinical-stage biotechnology company focused on human enzyme therapeutics to help people with serious and rare metabolic diseases with limited treatment options.
‘With his broad experience at both big pharma and emerging biotech and a strong intellectual property background, Jim brings a depth of experience that will be valuable as we advance our two clinical programs and evolve to a commercial-stage company,’ Aeglea president and CEO Anthony Quinn says in a statement. ‘I’m pleased to welcome Jim to the Aeglea team and look forward to working with him closely as we continue to execute on our corporate strategy.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
